Aekkachai Tuekprakhon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aekkachai Tuekprakhon has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Adamantia Zourou
School of Chemical Engineering, National Technical University of Athens, Zografou, 15773 Athens, Greece
2 shared publications - Alexandra Karagianni
Laboratory of Inorganic and Analytical Chemistry, School of Chemical Engineering, National Technical University of Athens, Athens, Greece
2 shared publications - Konstantinos Kordatos
School of Chemical Engineering, National Technical University of Athens, Zografou, 15773 Athens, Greece
2 shared publications - Zania Stamataki
Centre of Liver and Gastrointestinal for Research, Department of immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK
2 shared publications - Afroditi Ntziouni
School of Chemical Engineering, National Technical University of Athens, Zografou, 15773 Athens, Greece
1 shared publication - Aiste Dijokaite-Guraliuc
University of Oxford
1 shared publication
Latest Publications
- Open Access
Not All Heroes Wear Capes—Some Just Glow: Exploring Carbon Dots as Nanoagents Against COVID-19
The coronavirus disease (COVID-19) pandemic highlighted critical limitations in ongoing diagnostic and therapeutic strategies, underscoring the urgent need for alternative and complementary approaches. Carbon dots (CDs) represent a novel class of fluorescent carbon-based nanomaterials with increased research interest owing to their enhanced biocompatibility, tunable photoluminescence, aqueous solubility, and rich surface chemistry. This review outlines current approaches in the diagnosis and treatment of COVID-19, along with the main structural, physicochemical, and biological features of CDs. Recent advances in the application of CDs as biosensing and antiviral nanomaterials against SARS-CoV-2 are critically discussed with an emphasis on the influence of synthetic routes, precursor compounds, heteroatom doping, surface functionalization, and purification strategies on their optical behavior and biological performance. CD-based biosensors mainly rely on fluorescence-sensing strategies, exploiting changes in photoluminescence intensity or energy-transfer processes upon recognition of viral targets. Electrochemical approaches are also investigated, highlighting the role of CDs as electrode modifiers to enable sensitive immunodetection in complex biological samples. Apart from diagnosis, the therapeutic potential of CDs is underscored by inhibiting viral entry, replication, disrupting cell membranes, or modulating oxidative stress. Finally, current limitations, challenges, and future perspectives regarding mechanistic understanding, synthesis parameters, biodistribution, and clinical translation are discussed, demonstrating the potential of CDs as novel “shiny weapons” against COVID-19, combining therapeutic and diagnostic functions.
Open AccessNot All Heroes Wear Capes—Some Just Glow: Exploring Carbon Dots as Nanoagents Against COVID-19
The coronavirus disease (COVID-19) pandemic highlighted critical limitations in ongoing diagnostic and therapeutic strategies, underscoring the urgent need for alternative and complementary approaches. Carbon dots (CDs) represent a novel class of fluorescent carbon-based nanomaterials with increased research interest owing to their enhanced biocompatibility, tunable photoluminescence, aqueous solubility, and rich surface chemistry. This review outlines current approaches in the diagnosis and treatment of COVID-19, along with the main structural, physicochemical, and biological features of CDs. Recent advances in the application of CDs as biosensing and antiviral nanomaterials against SARS-CoV-2 are critically discussed with an emphasis on the influence of synthetic routes, precursor compounds, heteroatom doping, surface functionalization, and purification strategies on their optical behavior and biological performance. CD-based biosensors mainly rely on fluorescence-sensing strategies, exploiting changes in photoluminescence intensity or energy-transfer processes upon recognition of viral targets. Electrochemical approaches are also investigated, highlighting the role of CDs as electrode modifiers to enable sensitive immunodetection in complex biological samples. Apart from diagnosis, the therapeutic potential of CDs is underscored by inhibiting viral entry, replication, disrupting cell membranes, or modulating oxidative stress. Finally, current limitations, challenges, and future perspectives regarding mechanistic understanding, synthesis parameters, biodistribution, and clinical translation are discussed, demonstrating the potential of CDs as novel “shiny weapons” against COVID-19, combining therapeutic and diagnostic functions.
- Open Access
Carbon Dots-TiO2 Decorated with Ag Nanoparticles for Efficient Photocatalytic and Antiviral Applications
The modern world is confronting critical environmental and biomedical challenges, underscoring the urgent need for the development of multifunctional materials—an inherently interdisciplinary field, bridging materials science and engineering, environmental science and biomedicine. Titanium dioxide (TiO2) is widely recognized for its photocatalytic and antiviral properties, enabling the degradation of pollutants and mitigation of viral contamination under solar irradiation. Nevertheless, it exhibits certain limitations, such as wide band gap and high recombination rate of photogenerated electron–hole pairs. To address these limitations, TiO2 prepared by a co-precipitation method was modified with N-Doped Carbon Dots (N-CDs) via a hydrothermal treatment, which extend light absorption into the visible region and enhance charge separation. Further functionalization with silver nanoparticles (Ag NPs)—well known for their antimicrobial properties—via a simple thermal process under ambient conditions, introduced additional reactive oxygen species generation, creating a synergistic effect. The as-prepared TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag samples were characterized via several techniques, such as XRD, micro-Raman, FT-IR, TEM and UV-Vis. In addition, their photocatalytic and antiviral activity against methylene blue (MB) and nitrogen oxide (NOx) pollutants, as well as SARS-CoV-2, was evaluated. Based on the results of liquid-phase photocatalysis, TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag presented a degradation efficiency of 78%, 85% and 95%, respectively, whereas different trends were observed under gaseous-phase conditions. The TiO2/N-CDs/Ag hybrid material demonstrated superior antiviral activity against SARS-CoV-2 (IC50: 1.24 ± 0.34 g/L), compared to both TiO2 (IC50: 1.78 ± 0.30 g/L) and TiO2/N-CDs (IC50: >2.5 g/L), highlighting its potential as an effective multifunctional material. Finally, TiO2/N-CDs/Ag was incorporated onto a paper substrate, demonstrating antiviral activity, showing promising scalability for application across a wide range of future substrates. To the best of our knowledge, this is the first study presenting TiO2/N-CDs/Ag with dual photocatalytic and antiviral activity.
Open AccessCarbon Dots-TiO2 Decorated with Ag Nanoparticles for Efficient Photocatalytic and Antiviral Applications
The modern world is confronting critical environmental and biomedical challenges, underscoring the urgent need for the development of multifunctional materials—an inherently interdisciplinary field, bridging materials science and engineering, environmental science and biomedicine. Titanium dioxide (TiO2) is widely recognized for its photocatalytic and antiviral properties, enabling the degradation of pollutants and mitigation of viral contamination under solar irradiation. Nevertheless, it exhibits certain limitations, such as wide band gap and high recombination rate of photogenerated electron–hole pairs. To address these limitations, TiO2 prepared by a co-precipitation method was modified with N-Doped Carbon Dots (N-CDs) via a hydrothermal treatment, which extend light absorption into the visible region and enhance charge separation. Further functionalization with silver nanoparticles (Ag NPs)—well known for their antimicrobial properties—via a simple thermal process under ambient conditions, introduced additional reactive oxygen species generation, creating a synergistic effect. The as-prepared TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag samples were characterized via several techniques, such as XRD, micro-Raman, FT-IR, TEM and UV-Vis. In addition, their photocatalytic and antiviral activity against methylene blue (MB) and nitrogen oxide (NOx) pollutants, as well as SARS-CoV-2, was evaluated. Based on the results of liquid-phase photocatalysis, TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag presented a degradation efficiency of 78%, 85% and 95%, respectively, whereas different trends were observed under gaseous-phase conditions. The TiO2/N-CDs/Ag hybrid material demonstrated superior antiviral activity against SARS-CoV-2 (IC50: 1.24 ± 0.34 g/L), compared to both TiO2 (IC50: 1.78 ± 0.30 g/L) and TiO2/N-CDs (IC50: >2.5 g/L), highlighting its potential as an effective multifunctional material. Finally, TiO2/N-CDs/Ag was incorporated onto a paper substrate, demonstrating antiviral activity, showing promising scalability for application across a wide range of future substrates. To the best of our knowledge, this is the first study presenting TiO2/N-CDs/Ag with dual photocatalytic and antiviral activity.
- Open Access
- 13 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2349796
Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis
Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and adverse events. This study assessed the efficacy and safety of CAR T-cell therapy for r/r B-ALL. The literature search was performed on four databases. Efficacy parameters included minimal residual disease negative complete remission (MRD-CR) and relapse rate (RR). Safety parameters constituted cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Anti-CD22 showed superior efficacy with the highest MRD-CR event rate and lowest RR, compared to anti-CD19. Combining CAR T-cell therapy with haploidentical stem cell transplantation improved RR. Safety-wise, bispecific anti-CD19/22 had the lowest CRS rate, and anti-CD22 showed the fewest ICANS. Analysis of the costimulatory receptors showed that adding CD28ζ to anti-CD19 CAR T-cell demonstrated superior efficacy in reducing relapses with favorable safety profiles. Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.
- 13 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2349796
Open AccessComprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis
Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and adverse events. This study assessed the efficacy and safety of CAR T-cell therapy for r/r B-ALL. The literature search was performed on four databases. Efficacy parameters included minimal residual disease negative complete remission (MRD-CR) and relapse rate (RR). Safety parameters constituted cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Anti-CD22 showed superior efficacy with the highest MRD-CR event rate and lowest RR, compared to anti-CD19. Combining CAR T-cell therapy with haploidentical stem cell transplantation improved RR. Safety-wise, bispecific anti-CD19/22 had the lowest CRS rate, and anti-CD22 showed the fewest ICANS. Analysis of the costimulatory receptors showed that adding CD28ζ to anti-CD19 CAR T-cell demonstrated superior efficacy in reducing relapses with favorable safety profiles. Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.
- Open Access
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
Summary: Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to the detection of emerging drug resistance. Here we report the accrual of mutations in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the epitopes of the respective nmAbs. For casirivimab+imdevimab these are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.
Open AccessGenome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
Summary: Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to the detection of emerging drug resistance. Here we report the accrual of mutations in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the epitopes of the respective nmAbs. For casirivimab+imdevimab these are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.